Key Takeaways
- • Welltower (WELL) closed at $209.45 on April 20, 2026, with a market capitalization of approximately $147.45 billion and a 52-week range of $141.55–$216.43, positioning it as a large-cap healthcare REIT.
- • Analyst consensus rates WELL as "Buy" with a 12-month average price target of $225.43, implying approximately 7.6% upside from April 20 closing prices, with individual targets ranging from $183.00 to $246.00.
- • The stock has delivered strong performance year-to-date with 12.6% returns, 45.3% one-year returns, and 197.5% three-year returns, reflecting sustained investor conviction in the healthcare real estate sector.
- • Welltower reported a trailing P/E ratio of 140.63x, forward P/E of 85.47x, and a dividend yield of 1.48%, with earnings scheduled for April 28, 2026, generating institutional anticipation ahead of quarterly results.
- • The stock exhibits low systematic risk with a beta of 0.82, suggesting below-market volatility, while maintaining $5.03 billion in total cash and a total debt-to-equity ratio of approximately 49%, reflecting moderate leverage for the REIT structure.
Summary
Welltower Inc. (WELL) traded at $209.45 on April 20, 2026, within a daily range of $208.13–$211.03 and representing relative stability ahead of the company's Q1 2026 earnings release scheduled for April 28, 2026. The healthcare real estate investment trust maintained a market capitalization near $147.45 billion on strong institutional demand, with average trading volume of approximately 3.1 million shares daily. The stock's 52-week trading band of $141.55–$216.43 underscores volatility context, though the company's beta of 0.82 indicates below-market systematic risk exposure relative to the S&P 500.
Wall Street sentiment remains constructively positioned, with 12 analysts maintaining a consensus "Buy" rating and a blended 12-month price target of $225.43, representing potential upside of 7.6% from April 20 levels. Individual analyst price targets range from a low of $183.00 to a high of $246.00, reflecting divergent views on valuation and operational trajectory. Welltower's trailing twelve-month earnings per share of $1.42 corresponds to a trailing P/E ratio of 140.63x, while forward P/E stands at 85.47x—metrics reflecting the market's pricing for growth expectations relative to near-term earnings power. The company's forward dividend yield of 1.48% provides income support alongside price appreciation potential.
Year-to-date performance has been notably robust, with WELL generating 12.6% returns through April 20, supported by broader strength in healthcare real estate and demographic tailwinds favoring senior housing and medical office portfolios. The stock's longer-term trajectory—45.3% one-year returns and 197.5% three-year returns—demonstrates sustained investor conviction in the healthcare REIT sector and Welltower's operational execution. Fundamental metrics show trailing revenue of $10.84 billion and net income available to common shareholders of $936.84 million, producing a profit margin of 8.64%. The balance sheet reflects $5.03 billion in total cash against a debt-to-equity ratio of approximately 49%, positioning the company with moderate leverage appropriate for institutional real estate operations.
Welltower's valuation multiples—price-to-book of 3.34x, price-to-sales of 12.72x, and enterprise value-to-revenue of 14.72x—reflect premium positioning within the REIT peer set, consistent with leadership status in healthcare properties. The earnings announcement on April 28, 2026, will provide updated guidance and operational metrics that will likely influence institutional portfolio positioning and analyst target revisions. Current investor positioning suggests balanced conviction between accumulation on dips and profit-taking at resistance levels near the 52-week highs, with the stock's low beta and dividend support appealing to both growth and income-focused institutional allocators.
Wall Street sentiment remains constructively positioned, with 12 analysts maintaining a consensus "Buy" rating and a blended 12-month price target of $225.43, representing potential upside of 7.6% from April 20 levels. Individual analyst price targets range from a low of $183.00 to a high of $246.00, reflecting divergent views on valuation and operational trajectory. Welltower's trailing twelve-month earnings per share of $1.42 corresponds to a trailing P/E ratio of 140.63x, while forward P/E stands at 85.47x—metrics reflecting the market's pricing for growth expectations relative to near-term earnings power. The company's forward dividend yield of 1.48% provides income support alongside price appreciation potential.
Year-to-date performance has been notably robust, with WELL generating 12.6% returns through April 20, supported by broader strength in healthcare real estate and demographic tailwinds favoring senior housing and medical office portfolios. The stock's longer-term trajectory—45.3% one-year returns and 197.5% three-year returns—demonstrates sustained investor conviction in the healthcare REIT sector and Welltower's operational execution. Fundamental metrics show trailing revenue of $10.84 billion and net income available to common shareholders of $936.84 million, producing a profit margin of 8.64%. The balance sheet reflects $5.03 billion in total cash against a debt-to-equity ratio of approximately 49%, positioning the company with moderate leverage appropriate for institutional real estate operations.
Welltower's valuation multiples—price-to-book of 3.34x, price-to-sales of 12.72x, and enterprise value-to-revenue of 14.72x—reflect premium positioning within the REIT peer set, consistent with leadership status in healthcare properties. The earnings announcement on April 28, 2026, will provide updated guidance and operational metrics that will likely influence institutional portfolio positioning and analyst target revisions. Current investor positioning suggests balanced conviction between accumulation on dips and profit-taking at resistance levels near the 52-week highs, with the stock's low beta and dividend support appealing to both growth and income-focused institutional allocators.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.